Daiichi Sankyo to Launch Percutaneous Analgesic and Anti-Inflammatory Drug Loxonin(R) Gel 1% in Japan

For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 (Public Relations) +81-3-6225-1125 (Investor Relations) http://www.daiichisankyo.com/ Daiichi Sankyo to Launch Percutaneous Analgesic and Anti-Inflammatory Drug Loxonin(R) Gel 1% in Japan Tokyo, Japan (October 5, 2010) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the launch in Japan of its percutaneous analgesic and anti-inflammatory drug Loxonin® Gel 1% (generic name, loxoprofen sodium hydrate; approval for manufacture and marketing, June 9, 2010; drug price listing, September 24, 2010). Loxonin® Gel 1% contains the same active ingredient, loxoprofen sodium hydrate, as found in pills and powder formulations of the leading oral analgesic and anti-inflammatory Loxonin® brand. The gel offers equivalent efficacy and can be easily applied to an affected area with no displeasing odor. Following the launch of Loxonin® pap in 2006 and Loxonin® tape in 2008, Daiichi Sankyo is confident that this new addition to the Loxonin® lineup, which has been a long-standing top brand since 1986, will further contribute to analgesic and anti-inflammatory drug treatment in Japan. Product Outline (Launch date: October 5, 2010) Dosage form Percutaneous analgesic and anti-inflammatory drug Product name Loxonin® Gel 1% (generic name: loxoprofen sodium hydrate) Drug price 6.8 yen/g (25g package: 170 yen, 50g package: 340 yen) 【Japan standard drug price listing received September 24, 2010】 Efficacy Relieves pain and inflammation occurring from the following illnesses and symptoms: degenerative arthritis, muscle pain, swelling and pain caused by external injury Dosage Rub gel on an affected area once per day (appropriate amount dependent on symptoms) Remarks Manufacture and marketing: DAIICHI SANKYO Co., Ltd. End

The release as fetched from its publisher. daiichisankyo.com ↗